Evidence map›Paper›PMID 34848425›Full record

ArticleBMJ case reports2021

COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis.

Kazuki Takasaki, Takazumi Tsunenari, Kazuma Mori, Satsuki Aochi

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kazuki TakasakiObstetrics and Gynecology, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan frantic_pace_of_dying@yahoo.co.jp.ORCID http://orcid.org/0000-0001-6671-1858
Takazumi TsunenariSurgery, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.
Kazuma MoriInternal Medicine, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.
Satsuki AochiInternal Medicine, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients.

Indexed as

COVID-19Thrombocythemia, EssentialAdultFibrinolytic AgentsHumansMalePyrazolesPyridonesSARS-CoV-2apixabanFibrinolytic AgentsPyrazolesPyridonesCOVID-19medical management

Identifiers

PMID34848425
PMCPMC8634247
OpenAlexW3215910418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.